Evidence map›Paper›PMID 28738266›Full record

ArticleDrug and alcohol dependence2017

ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation.

L Cinnamon Bidwell, Hollis C Karoly, Kent E Hutchison, Angela D Bryan

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

L Cinnamon BidwellInstitute of Cognitive Science, University of Colorado Boulder, UCB 344, Boulder, CO 80309-0345, USA. Electronic address: lcb@colorado.edu.
Hollis C KarolyDepartment of Psychology and Neuroscience, University of Colorado Boulder, UCB 344, Boulder, CO 80309-0345, USA. Electronic address: hollis.karoly@colorado.edu.
Kent E HutchisonInstitute of Cognitive Science, University of Colorado Boulder, UCB 344, Boulder, CO 80309-0345, USA; Department of Psychology and Neuroscience, University of Colorado Boulder, UCB 344, Boulder, CO 80309-0345, USA. Electronic address: kent.hutchison@colorado.edu.
Angela D BryanInstitute of Cognitive Science, University of Colorado Boulder, UCB 344, Boulder, CO 80309-0345, USA; Department of Psychology and Neuroscience, University of Colorado Boulder, UCB 344, Boulder, CO 80309-0345, USA. Electronic address: angela.bryan@colorado.edu.
University of Colorado Boulder · US

Funding

Effectiveness of Varenicline: Testing Individual DifferencesR01DA025074 · NIDA · THE MIND RESEARCH NETWORK · PI HUTCHISON, KENT E. · 2009 to 2014
$2.9M
Deconstructing the Smoking and ADHD Comorbidity: A Multilevel Genetic ApproachK23DA033302 · NIDA · UNIVERSITY OF COLORADO · PI BIDWELL, L. CINNAMON · 2012 to 2016
$871k
NIDA NIH HHS K23 DA033302NIDA NIH HHS R01 DA025074
6 · The paper itself

Abstract

introductionAttention-Deficit/Hyperactivity Disorder (ADHD) is associated with nicotine dependence and difficulty quitting smoking. Few cessation trials specifically consider the impact of ADHD on treatment outcomes, including those testing established pharmacological therapies, such as varenicline.

methodsThe current study focused on the impact of pretreatment ADHD inattention (IN) and hyperactivity-impulsivity (HI) symptoms on treatment outcome in a randomized controlled trial of varenicline [N=205, average age=34.13(10.07), average baseline cigarettes per day=14.71(7.06)]. Given that varenicline's putative therapeutic mechanism is attenuation of withdrawal severity during abstinence, we also tested changes in withdrawal as a mediator of treatment effects in high and low ADHD groups.

resultsADHD symptom severity in this sample was in the subclinical range. Cessation was associated with HI, but not IN, such that high HI individuals on varenicline reported the lowest smoking levels at the end of treatment across all groups (3.06cig/day for high HI vs 4.02cig/day for low HI). Individuals with high HI who received placebo had the highest smoking at the end of treatment (7.69cigs/day for high HI vs 5.56cig/day for low HI). Patterns continued at follow-up. Varenicline significantly reduced withdrawal for those with high HI, but not low HI. However, path models did not support an indirect effect of medication on reducing smoking via withdrawal in either group, suggesting that unmeasured variables are involved in varenicline's effect on reducing smoking.

conclusionsThese data add to a gap in the smoking cessation literature regarding the impact of ADHD symptoms on the efficacy and mechanisms of frontline pharmacological treatments.

Indexed as

Smoking CessationAttention Deficit Disorder with HyperactivityConduct DisorderHumansHyperkinesisImpulsive BehaviorSmokingTobacco Use DisorderTreatment OutcomeVareniclineVareniclineImpulsivityInattentionNicotineQuitting smokingWithdrawal

Identifiers

PMID28738266
PMCPMC5599352
OpenAlexW2739356510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.